Why Is Penny Stock HOOKIPA Pharma Trading Higher On Wednesday? [Yahoo! Finance]
HOOKIPA Pharma Inc. (HOOK)
Last hookipa pharma inc. earnings: 3/19 07:00 am
Check Earnings Report
Company Research
Source: Yahoo! Finance
In January, Roche terminated the collaboration and licensing agreement for HOOKIPA's HB-700 program in KRAS mutated cancers. HOOKIPA's HB-700 program is designed to treat KRAS-mutated lung, colorectal, pancreatic, and other cancers by targeting the five most prevalent KRAS mutations in these disease indications: G12D, G12V, G12R, G12C, and G13D. The company says the program can benefit more patients than single mutation inhibitors. The IND submission achieves a final $10 million milestone payment from Roche Holdings AG (OTC: RHHBY Effective April 25, 2024, the company will regain full control of the associated intellectual property portfolio and have full collaboration and licensing rights for the HB-700 program. The company will publish preclinical data in an abstract at the American Society for Clinical Oncology (ASCO) 2024 Annual Meeting. “We are proud to have another IND cleared for a potentially powerful oncology program. Our HB-700 program targets five KRAS mutation
Show less
Read more
Impact Snapshot
Event Time:
HOOK
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
HOOK alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
HOOK alerts
High impacting HOOKIPA Pharma Inc. news events
Weekly update
A roundup of the hottest topics
HOOK
News
- Hookipa Pharma Inc (NASDAQ: HOOK) had its price target lowered by analysts at HC Wainwright from $6.50 to $5.00. They now have a "buy" rating on the stock.MarketBeat
- HOOKIPA Pharma Announces Pivotal Phase 2/3 Trial Design for HB-200 in Combination with Pembrolizumab [Yahoo! Finance]Yahoo! Finance
- HOOKIPA Pharma Announces Pivotal Phase 2/3 Trial Design for HB-200 in Combination with PembrolizumabGlobeNewswire
- HOOKIPA Pharma Announces FDA Clearance of its Investigational New Drug Application for HB-700 for the Treatment of KRAS-Mutated Cancers [Yahoo! Finance]Yahoo! Finance
- HOOKIPA Pharma Announces FDA Clearance of its Investigational New Drug Application for HB-700 for the Treatment of KRAS-Mutated CancersGlobeNewswire
HOOK
Earnings
- 3/22/24 - Miss
HOOK
Sec Filings
- 4/26/24 - Form ARS
- 4/26/24 - Form DEFA14A
- 4/26/24 - Form DEF
- HOOK's page on the SEC website